The Library
Zoledronate extends health span and survival via the mevalonate pathway in a FOXO-dependent manner
Tools
Chen, Zhengqi, Cordero, Julia, Alqarni, Adel M., Slack, Cathy, Zeidler, Martin P., Bellantuono, Ilaria and Anderson, Rozalyn M. (2022) Zoledronate extends health span and survival via the mevalonate pathway in a FOXO-dependent manner. The Journals of Gerontology : Series A, 77 (8). pp. 1494-1502. doi:10.1093/gerona/glab172 ISSN 1079-5006.
|
PDF
glab172.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (6Mb) | Preview |
Official URL: http://doi.org/10.1093/gerona/glab172
Abstract
Over recent decades, increased longevity has not been paralleled by extended health span, resulting in more years spent with multiple diseases in older age. As such, interventions to improve health span are urgently required. Zoledronate (Zol) is a nitrogen-containing bisphosphonate, which inhibits the farnesyl pyrophosphate synthase enzyme, central to the mevalonate pathway. It is already used clinically to prevent fractures in osteoporotic patients, who have been reported to derive unexpected and unexplained survival benefits. Using Drosophila as a model we determined the effects of Zol on life span, parameters of health span (climbing ability and intestinal dysplasia), and the ability to confer resistance to oxidative stress using a combination of genetically manipulated Drosophila strains and Western blotting. Our study shows that Zol extended life span, improved climbing activity, and reduced intestinal epithelial dysplasia and permeability with age. Mechanistic studies showed that Zol conferred resistance to oxidative stress and reduced accumulation of X-ray-induced DNA damage via inhibition of farnesyl pyrophosphate synthase. Moreover, Zol was associated with inhibition of phosphorylated AKT in the mammalian traget of rapamycin pathway downstream of the mevalonate pathway and required dFOXO for its action, both molecules associated with increased longevity. Taken together, our work indicates that Zol, a drug already widely used to prevent osteoporosis and dosed only once a year, modulates important mechanisms of aging. Its repurposing holds great promise as a treatment to improve health span.
Item Type: | Journal Article | ||||||||
---|---|---|---|---|---|---|---|---|---|
Subjects: | Q Science > QP Physiology | ||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Science > Life Sciences (2010- ) | ||||||||
Library of Congress Subject Headings (LCSH): | Aging -- Health aspects , Diphosphonates -- Therapeutic use, Drosophila, Longevity -- Psychological aspects | ||||||||
Journal or Publication Title: | The Journals of Gerontology : Series A | ||||||||
Publisher: | Oxford University Press | ||||||||
ISSN: | 1079-5006 | ||||||||
Official Date: | August 2022 | ||||||||
Dates: |
|
||||||||
Volume: | 77 | ||||||||
Number: | 8 | ||||||||
Page Range: | pp. 1494-1502 | ||||||||
DOI: | 10.1093/gerona/glab172 | ||||||||
Status: | Peer Reviewed | ||||||||
Publication Status: | Published | ||||||||
Access rights to Published version: | Open Access (Creative Commons) | ||||||||
Date of first compliant deposit: | 18 May 2023 | ||||||||
Date of first compliant Open Access: | 18 May 2023 |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year